Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.75 |
| ▸ | EGFR | P00533 | 8/20 | 0.67 |
| ▸ | ABL1 | P00519 | 6/20 | 0.67 |
| ▸ | ABL2 | P42684 | 6/20 | 0.67 |
| ▸ | CDK1 | P06493 | 5/20 | 0.67 |
| ▸ | KDR | P35968 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | CSK | P41240 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22604442 | 0.87 | SRC (1.00) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL20912365 | 0.86 | SRC (0.67) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL20912346 | 0.84 | SRC (0.70) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL20912272 | 0.82 | SRC (0.50) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL20911785 | 0.82 | SRC (0.84) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7843386 | 0.81 | SRC (1.00) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL7058330 | 0.80 | PIK3CD (0.55) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL20912240 | 0.80 | SRC (0.76) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL20912117 | 0.80 | SRC (0.71) | SRCEGFRABL1ABL2CDK1 | |
| SCHEMBL22084743 | 0.79 | SRC (0.84) | SRCEGFRABL1ABL2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20200339583-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-10-29 | — | — | US | disclosed |
| WO-2019073253-A1 | MAP4K4 INHIBITORS | IMPERIAL INNOVATIONS LIMITED (GB) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339583-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K2, MAP4K5 | SRC 594/4885EGFR 1033/4885ABL1 82/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | SRC 594/4885EGFR 1033/4885ABL1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.